Expert panel recommends permission for phase 1 clinical trial of Bharat Biotech’s nasal vaccine

NEW DELHI: An expert panel of India’s drug regulator CDSCO on Tuesday recommended granting permission for conducting phase 1 clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.

A top Government official said that if this vaccine works it can be a game changer in the fight against COVID-19.

Bharat Biotech applied to the Drugs Controller General of India (DCGI) seeking permission for conducting phase 1 and phase 2 clinical trials of the intranasal vaccine following which the subject expert committee of the CDSCO on Tuesday deliberated on the application and recommended granting permission for phase 1 trial. (AGENCIES)